Kyntra Bio, Inc. (NasdaqGS: KYNB)
Health Care · Biotechnology · US
$4.58
-12.26% today · -57.2% 1Y
Kyntra Bio, Inc. (NasdaqGS: KYNB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $18.55M and employs 34 people.
Over the last twelve months the share price has lost 57.2%, trading between 4.85 and 11.65.
Tweenvest scores Kyntra Bio, Inc. across four factors: quality 32/100, value 36/100, growth 0/100. Its strongest factor is value.
KYNB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $18.55M
- Revenue (TTM)
- $4.62M
- P/E
- —
- EPS
- 45.27
- Dividend yield
- —
- Beta (5Y)
- 1.05
- 52-week high
- $11.65
- 52-week low
- $4.85
- Avg volume (3M)
- —
- Shares outstanding
- 4.05M
- Employees
- 34
- Next earnings
- —
About Kyntra Bio, Inc.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
- ISIN
- US31572Q8814
- Founded
- 1993
- Listed since
- Nov 14, 2014
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| General Biologicals CorporationTPEX: 4117 | $18.79M | NT$8.61 | -8.31% |
| Quoin Pharmaceuticals, Ltd.NasdaqCM: QNRX | $18.74M | $3.90 | -13.33% |
| Estrella Immunopharma, Inc.NasdaqCM: ESLA | $18.70M | $0.43 | +4.88% |
| Akari Therapeutics, PlcNasdaqCM: AKTX | $18.69M | $8.18 | -6.73% |
| Defence Therapeutics Inc.CNSX: DTC | $18.22M | CA$0.34 | -15.00% |
| Neuphoria Therapeutics Inc.NasdaqGM: NEUP | $17.86M | $3.30 | -1.79% |
| CCME Global LimitedBSE: 514336 | $17.68M | Rs37.09 | +15.44% |
| Perseus Proteomics Inc.TSE: 4882 | $17.63M | ¥151.00 | -1.31% |
Figures last refreshed Oct 18, 2026.